NVAX — NOVAVAX INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1000694 ·
Last close
$9.50
Market Cap
$1.56B
52W High
$11.61
52W Low
$7.57
ADV30
5,916,368
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 139,514,000 | 108,819,000 | -15,430,000 | -9,491,000 | 1,043,162,000 | 228,363,000 | 1,187,924,000 |
| Dec 2025 | 147,139,000 | 125,035,000 | 15,037,000 | 17,527,000 | 1,176,512,000 | 240,634,000 | 1,304,265,000 |
| Sep 2025 | 70,445,000 | 48,949,000 | -80,980,000 | -202,379,000 | 1,179,889,000 | 268,023,000 | 1,336,561,000 |
| Jun 2025 | 239,240,000 | 223,915,000 | 101,070,000 | 106,508,000 | 1,336,549,000 | 253,744,000 | 1,298,924,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-244,635,000
Investing CF
$-78,267,000
Financing CF
$27,737,000
CapEx
$-6,388,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.41
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-4,568,148,000
Inventory
$11,545,000
Receivables
$106,446,000
ST Investments
$494,450,000
EBIT TTM
$464,714,000
Pretax Income TTM
$442,167,000
Interest Exp TTM
$22,547,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$596,337,984
EBITDA
$59,532,000
Free Cash Flow
$58,573,936
Enterprise Value
$1,017,556,672
Total Cash
$790,332,032
Total Debt
$295,057,984
Shares Out
164,438,119
Trailing EPS
$-0.56
Book Value
$-0.88
ROE
—
ROA
2.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,123,479,000 | 550,640,000 | 440,302,000 | 1,176,512,000 | 1,304,265,000 | — | -244,635,000 |
| Dec 2024 | 682,162,000 | -248,931,000 | -187,499,000 | 1,560,418,000 | 2,184,259,000 | — | -87,263,000 |
| Dec 2023 | 556,382,000 | -566,511,000 | -545,062,000 | 1,797,490,000 | 2,514,417,000 | — | -713,967,000 |
| Dec 2022 | 1,598,951,000 | -644,736,000 | -657,939,000 | 2,258,679,000 | 2,892,757,000 | — | -415,937,000 |
TTM Snapshot
Revenues TTM
$1,184,919,000
NetIncome TTM
$-743,120,000
OpCashFlow TTM
$0
Assets (Latest)
$1,560,418,000
Forward EPS
$-0.54
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.50 · call volume: 1,160 · put volume: 580
Expected Move to 2027-01-15:
±$4.75
(50.00%) —
implied range
$4.75 –
$14.25
· ATM straddle on $9.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VIR | Vir Biotechnology, Inc. | $1.57B | $9.30 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.56B | $18.41 | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.63B | $3.11 | — |
| IMCR | Immunocore Holdings plc | $1.45B | $28.55 | — |
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $1.75B | $3.93 | — |
News headlines (Yahoo Finance, 1h cache)
Moderna Is Up 94% This Year: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?
2026-06-16 19:21 · Yahoo
A Look Back at Therapeutics Stocks’ Q1 Earnings: Novavax (NASDAQ:NVAX) Vs The Rest Of The Pack
2026-06-16 18:33 · Yahoo
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
2026-06-12 21:45 · Yahoo
Novavax Pivots To Matrix M Licensing As Sanofi Takes Europe
2026-06-11 00:20 · Yahoo
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
2026-06-08 13:00 · Yahoo
Novavax (NVAX) Up 10.4% Since Last Earnings Report: Can It Continue?
2026-06-05 15:30 · Yahoo
3 Cash-Burning Stocks We Think Twice About
2026-06-04 17:33 · Yahoo
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
2026-06-01 20:00 · Yahoo
Why Novavax (NVAX) Stock Is Trading Up Today
2026-05-26 20:15 · Yahoo
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
2026-05-26 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.